Treatment of Medication-related osteonecrosis of the jaw: a clinical examination

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009411

Enrollment

200

Registered

2016-10-13

Start date

2016-10-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M87.18

Interventions

Group 1: Follow-up examination of patients who unterwent surgery for Medication-Related Osteonecrosis of the Jaws, related to treatment with either bisphosphonates, Denosumab or bisphosphonates and De

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients of the department of oral- and maxillofacial surgery who have been diagnosed with MRONJ, according to the definition of AAOMS, and therefore were treated surgically.

Exclusion criteria

Exclusion criteria: Patients with a history of radiation to the jaws or obvious metastatic disease to the jaws

Design outcomes

Primary

Measure	Time frame
Percentage of patients with recurrent MRONJ after treatment.	—

Secondary

Measure	Time frame
Effect of given antiresorptive agent - Bisphosphonates, Denosumab, Bisphosphonates and Denosumab - on: - likeliness of development of recurrent MRONJ - clinical stage of present MRONJ - post-therapeutic course	—

Countries

Germany

Contacts

Public ContactPit Jacob Voss

Klinik für Mund-, Kiefer- und Gesichtschirurgie

pit.voss@uniklinik-freiburg.de0761 270-49950

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026